Genmab | GEN - Interest Expense On Debt


Genmab reported DKK139M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Amarin USD 3K 5K Dec/2024
Amgen USD 653M 94.99B Sep/2026
argenx SE USD 1000K 0 Sep/2026
AstraZeneca USD 371M 31M Sep/2026
Bayer EUR 675M 87M Dec/2025
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Demant DKK 424M 26M Jun/2026
Exelixis USD 23.4M 3.9M Sep/2023
Fresenius Medical Care EUR 97.5M 14.5M Sep/2026
Genmab DKK 139M 129M Jun/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
GN Store Nord DKK 154M 132M Sep/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
Insmed USD 20.41M 1.57M Sep/2026
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Lonza CHF 84M 14M Jun/2025
Merck EUR 119M 18M Sep/2026
Novartis USD 468M 6M Sep/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 222M 65M Sep/2026
UCB EUR 49M 29M Dec/2025